LOS ANGELES, CA – May 22, 2012– Ritter Pharmaceuticals, Inc. presented its abstract summarizing results from its Phase 2 study of RP-G28, a first-in-class treatment for lactose intolerance at the annual international Digestive Disease Week (DDW) 2012®. DDW is considered the largest meeting in the world for physicians and researchers in the fields of gastroenterology, hepatology, endoscopy, and gastrointestinal surgery.
The abstract was presented by Dennis Savaiano, Ph.D., who is the chairman of Ritter’s Medical Advisory Board and Professor of Nutrition Science at Purdue University. The presentation discussed the importance of a lactose intolerance treatment and highlighted Ritter’s Phase 2 clinic on RP-G28 which demonstrated that RP-G28 improves digestive symptoms associated with lactose intolerance while changing the intestinal bacterial population and reducing breath hydrogen production (a commonly used diagnostic test for lactose maldigestion).
“I am pleased to have the opportunity to discuss and share clinical trial results on RP-G28,” said Dennis Savaiano. “Proving mechanism of action for a treatment for lactose intolerance is an exciting accomplishment.”
This study marks a major milestone in lactose intolerance research as it represents the first controlled Phase 2 study for a prescription drug candidate for patients with lactose intolerance.
“Presenting at DDW 2012 in front of the gastrointestinal community was a great opportunity for our company and for RP-G28,” said Andrew Ritter, President and CEO of Ritter Pharmaceuticals. “The results provide evidence that RP-G28 is a potentially condition-modifying treatment, in that the symptom reduction and the changes in bacterial population persisted for a month after stopping drug treatment.”
RP‐G28 has the potential to become the first FDA‐approved drug for the treatment of lactose intolerance. RP‐G28 is a proprietary oligosaccharide that is orally administered for a set treatment period. The effect of RP-G28 is to induce a change in colon microbe populations which enables lactose digestion. After a single treatment cycle, patients experience a sustained ability to consume dairy products.
About Lactose Intolerance
Lactose intolerance is a common gastrointestinal condition often causing debilitating and painful symptoms from the consumption of dairy products. Globally, over 1 billion people are lactose intolerant, 39 million of whom are estimated to live in the United States. People with lactose intolerance have insufficient lactase, the enzyme lining the small bowel and responsible for breaking down lactose (“milk sugar”). The result is one or more gastrointestinal symptoms; including abdominal pain, cramps, bloating, gas, and/or diarrhea following the ingestion of lactose-containing foods.
About Ritter Pharmaceuticals, Inc
Ritter is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Ritter is rapidly establishing itself as a world’s leader in lactose intolerance research. For additional information, please visit www.RitterPharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the clinical development of Ritter’s drug candidate, RP-G28, and RP-G28′s potential to treat the symptoms associated with lactose intolerance. Words such as “intended”, “potential” and similar words and expressions identify forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Ritter that any of its plans will be achieved. Future results can be affected by inaccurate assumptions and by known or unknown risks and uncertainties. For example, statements relating to Ritter’s ongoing clinical trials may turn out to be wrong because, among other things, Ritter’s product candidates may prove to be ineffective and planned studies could be delayed as a result of actions by third parties upon whom Ritter relies or Ritter’s own lack of financial resources. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Ritter undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.